Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology
share announcement

Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 6444

Special Issue Editor

Dr. Nelson Yee

E-Mail Website
Guest Editor
Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850, USA
Interests: cancer biomarkers, cancer therapy, clinical investigation, machine learning, translational research
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancers in digestive organs represent the most common malignant diseases, and they pose a major challenge to global public health. Although patients diagnosed with localized cancers can be treated with curable intent, tumor recurrence can occur at high rates. For patients with advanced unresectable or metastatic diseases, systemic treatment and/or palliative care remain the only options. Due to tumor heterogeneity among patients and between tumor sites in the same patient, the possibility of adopting effective personalized medicine for all patients remains a highly unmet need. As translational research has led to significant advances in screening and patient management, the individualized diagnosis, treatment, and prognosis of gastrointestinal tumors have become important clinical and research focuses.

This Special Issue of Journal of Personalized Medicine focuses on the screening, early detection, diagnosis, prevention, and clinical investigation of gastrointestinal cancer, including but not limited to multi-modality therapy, markers, imaging, and tumor biology.

Dr. Nelson Yee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastrointestinal oncology
  • genomics
  • proteomics
  • biomarkers
  • circulating tumor cells
  • tumor heterogeneity
  • tumor biology
  • liquid biopsy
  • extracellular vesicles
  • machine learning

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

10 pages, 533 KiB  
Article
Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data
by Afsaneh Barzi, Angela J. Kim, Crystal K. Liang, Howard West, D. Wong, Carol Wright, Nitya Nathwani, Catherine M. Vasko, Vincent Chung, Douglas A. Rubinson and Todd Sachs
J. Pers. Med. 2023, 13(9), 1377; https://doi.org/10.3390/jpm13091377 - 15 Sep 2023
Viewed by 1366
Abstract
Background: Pancreatic adenocarcinoma is an aggressive disease and the delivery of comprehensive care to individuals with this cancer is critical to achieve appropriate outcomes. The identification of gaps in care delivery facilitates the design of interventions to optimize care delivery and improve outcomes [...] Read more.
Background: Pancreatic adenocarcinoma is an aggressive disease and the delivery of comprehensive care to individuals with this cancer is critical to achieve appropriate outcomes. The identification of gaps in care delivery facilitates the design of interventions to optimize care delivery and improve outcomes in this population. Methods: AccessHope™ is a growing organization that connects oncology subspecialists with treating providers through contracts with self-insured employers. Data from 94 pancreatic adenocarcinoma cases (August 2019–December 2022) in the AccessHope dataset were used to describe gaps in care delivery. Results: In all but 6% of cases, the subspecialist provided guideline-concordant recommendations anticipated to improve outcomes. Gaps in care were more pronounced in patients with non-metastatic pancreatic cancer. There was a significant deficiency in germline testing regardless of the stage, with only 59% of cases having completed testing. Only 20% of cases were receiving palliative care or other allied support services. There was no difference in observed care gaps between patients receiving care in the community setting vs. those receiving care in the academic setting. Conclusions: There are significant gaps in the care delivered to patients with pancreatic adenocarcinoma. A concurrent subspecialist review has the opportunity to identify and address these gaps in a timely manner. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology)
►▼ Show Figures

Figure 1

11 pages, 1313 KiB  
Article
Combining Preoperative Clinical and Imaging Characteristics to Predict MVI in Hepatitis B Virus-Related Combined Hepatocellular Carcinoma and Cholangiocarcinoma
by Si-Si Huang, Meng-Xuan Zuo and Chuan-Miao Xie
J. Pers. Med. 2023, 13(2), 246; https://doi.org/10.3390/jpm13020246 - 29 Jan 2023
Cited by 1 | Viewed by 1418
Abstract
Background: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA) is a rare form of primary liver malignancy. Microvascular invasion (MVI) indicates poor postsurgical prognosis in cHCC-CCA. The objective of this study was to investigate preoperative predictors of MVI in hepatitis B virus (HBV) -related cHCC-CCA [...] Read more.
Background: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CCA) is a rare form of primary liver malignancy. Microvascular invasion (MVI) indicates poor postsurgical prognosis in cHCC-CCA. The objective of this study was to investigate preoperative predictors of MVI in hepatitis B virus (HBV) -related cHCC-CCA patients. Methods: A total of 69 HBV-infected patients with pathologically confirmed cHCC-CCA who underwent hepatectomy were included. Univariate and multivariate analyses were conducted to determine independent risk factors that were then incorporated into the predictive model associated with MVI. Receiver operating characteristic analysis was used to assess the predictive performance of the new model. Results: For the multivariate analysis, γ-glutamyl transpeptidase (OR, 3.69; p = 0.034), multiple nodules (OR, 4.41; p = 0.042) and peritumoral enhancement (OR, 6.16; p = 0.004) were independently associated with MVI. Active replication of HBV indicated by positive HBeAg showed no differences between MVI-positive and MVI-negative patients. The prediction score using the independent predictors achieved an area under the curve of 0.813 (95% CI 0.717–0.908). A significantly lower recurrence-free survival was observed in the high-risk group with a score of ≥1 (p < 0.001). Conclusion: γ-glutamyl transpeptidase, peritumoral enhancement and multiple nodules were independent preoperative predictors of MVI in HBV-related cHCC-CCA patients. The established prediction score demonstrated satisfactory performance in predicting MVI pre-operatively and may facilitate prognostic stratification. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

13 pages, 615 KiB  
Review
Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment
by Sasha Waldstein, Marianne Spengler, Iryna V. Pinchuk and Nelson S. Yee
J. Pers. Med. 2023, 13(7), 1114; https://doi.org/10.3390/jpm13071114 - 10 Jul 2023
Viewed by 1891
Abstract
Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. [...] Read more.
Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for known mutational differences, tumor side of origin has emerged as an independent prognostic factor, and one that impacts response to therapy. Left- and right-sided colon cancers differ in a number of key ways, including histology, mutational profile, carcinogenesis pathways, and microbiomes. Moreover, the frequency of certain molecular features gradually changes from the ascending colon to rectum. These, as well as features yet to be identified, are likely responsible for the ongoing role of tumor sidedness and colorectal subsites in treatment response and prognosis. Along with tumor molecular profiling, blood-based biopsy enables the identification of targetable mutations and predictive biomarkers of treatment response. With the application of known tumor characteristics including sidedness and subsites as well as the utilization of blood-based biopsy, along with the development of biomarkers and targeted therapies, the field of colorectal cancer continues to evolve towards the personalized management of a heterogeneous cancer. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

11 pages, 6171 KiB  
Technical Note
Perineal Hernia Mesh Repair Using Only the Perineal Approach: How We Do It
by Emil Moiș, Florin Graur, Levente Horvath, Luminița Furcea, Florin Zaharie, Dan Vălean, Septimiu Moldovan and Nadim Al Hajjar
J. Pers. Med. 2023, 13(10), 1456; https://doi.org/10.3390/jpm13101456 - 30 Sep 2023
Viewed by 1241
Abstract
Perineal hernia is a rare complication of rectal surgery. Different types of surgical approach have been described, but none of them have proven their superiority. Although there are many methods of closing the defect, we selected two cases to present from a series [...] Read more.
Perineal hernia is a rare complication of rectal surgery. Different types of surgical approach have been described, but none of them have proven their superiority. Although there are many methods of closing the defect, we selected two cases to present from a series of five cases, in which the perineal hernia was successfully resolved surgically using only the perineal approach. The reconstruction of the perineal floor and closure of the defect were performed using a synthetic polypropylene mesh. The significance of this Technical Note article lies in the fact that we describe, step by step, a surgical technique for perineal hernia using just a perineal approach. Full article
(This article belongs to the Special Issue Personalized Diagnosis, Treatment, and Prognosis of Gastrointestinal Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop